Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. DSX
2. GNK
3. INTC
4. III
5. TTEC
6. DAL
7. AWK
8. SPCX
9. KWM
10. RAY-A

Go back to Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
AGIOS PHARM (NASDAQ: AGIO) Delayed: 34.16 +1.08 (3.26%)
Previous Close $33.08    52 Week High $71.49 
Open $33.90    52 Week Low $33.50 
Day High $34.45    P/E N/A 
Day Low $33.50    EPS $-1.18 
Volume 2,241,589